VOR vs. KRRO, PRME, NVCT, ACIU, ZYBT, BTMD, ELDN, YMAB, LFVN, and SOPH
Should you be buying Vor Biopharma stock or one of its competitors? The main competitors of Vor Biopharma include Korro Bio (KRRO), Prime Medicine (PRME), Nuvectis Pharma (NVCT), AC Immune (ACIU), Zhengye Biotechnology (ZYBT), biote (BTMD), Eledon Pharmaceuticals (ELDN), Y-mAbs Therapeutics (YMAB), LifeVantage (LFVN), and SOPHiA GENETICS (SOPH). These companies are all part of the "pharmaceutical products" industry.
Vor Biopharma vs.
Vor Biopharma (NYSE:VOR) and Korro Bio (NASDAQ:KRRO) are both small-cap medical companies, but which is the superior business? We will contrast the two businesses based on the strength of their profitability, analyst recommendations, institutional ownership, community ranking, dividends, risk, earnings, media sentiment and valuation.
Vor Biopharma has a beta of -0.4, suggesting that its stock price is 140% less volatile than the S&P 500. Comparatively, Korro Bio has a beta of 2.13, suggesting that its stock price is 113% more volatile than the S&P 500.
97.3% of Vor Biopharma shares are held by institutional investors. Comparatively, 13.2% of Korro Bio shares are held by institutional investors. 4.7% of Vor Biopharma shares are held by company insiders. Comparatively, 5.4% of Korro Bio shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock will outperform the market over the long term.
Vor Biopharma presently has a consensus price target of $8.86, indicating a potential upside of 929.90%. Korro Bio has a consensus price target of $142.57, indicating a potential upside of 525.45%. Given Vor Biopharma's higher possible upside, analysts plainly believe Vor Biopharma is more favorable than Korro Bio.
Vor Biopharma's return on equity of 0.00% beat Korro Bio's return on equity.
In the previous week, Korro Bio had 9 more articles in the media than Vor Biopharma. MarketBeat recorded 26 mentions for Korro Bio and 17 mentions for Vor Biopharma. Korro Bio's average media sentiment score of 0.39 beat Vor Biopharma's score of -0.06 indicating that Korro Bio is being referred to more favorably in the news media.
Vor Biopharma has higher earnings, but lower revenue than Korro Bio. Korro Bio is trading at a lower price-to-earnings ratio than Vor Biopharma, indicating that it is currently the more affordable of the two stocks.
Vor Biopharma received 30 more outperform votes than Korro Bio when rated by MarketBeat users. However, 100.00% of users gave Korro Bio an outperform vote while only 70.89% of users gave Vor Biopharma an outperform vote.
Summary
Vor Biopharma and Korro Bio tied by winning 8 of the 16 factors compared between the two stocks.
Get Vor Biopharma News Delivered to You Automatically
Sign up to receive the latest news and ratings for VOR and its competitors with MarketBeat's FREE daily newsletter.
New MarketBeat Followers Over Time
This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Media Sentiment Over Time
This chart shows the average media sentiment of NYSE and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Vor Biopharma Competitors List
Related Companies and Tools
This page (NYSE:VOR) was last updated on 3/25/2025 by MarketBeat.com Staff
